RBO & Co. LLC trimmed its stake in shares of Abbott Laboratories (NYSE:ABT) by 6.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 235,437 shares of the healthcare product maker’s stock after selling 15,277 shares during the period. Abbott Laboratories comprises about 3.6% of RBO & Co. LLC’s portfolio, making the stock its 5th largest position. RBO & Co. LLC’s holdings in Abbott Laboratories were worth $14,359,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of ABT. Charles Schwab Investment Advisory Inc. acquired a new stake in shares of Abbott Laboratories during the second quarter worth $275,697,000. American Century Companies Inc. raised its holdings in shares of Abbott Laboratories by 417.9% during the second quarter. American Century Companies Inc. now owns 5,586,119 shares of the healthcare product maker’s stock worth $340,697,000 after acquiring an additional 4,507,553 shares during the period. BlackRock Inc. raised its holdings in shares of Abbott Laboratories by 3.7% during the second quarter. BlackRock Inc. now owns 116,149,740 shares of the healthcare product maker’s stock worth $7,083,972,000 after acquiring an additional 4,153,157 shares during the period. Swedbank acquired a new stake in shares of Abbott Laboratories during the second quarter worth $101,535,000. Finally, Ceredex Value Advisors LLC acquired a new stake in shares of Abbott Laboratories during the first quarter worth $97,236,000. Institutional investors and hedge funds own 72.48% of the company’s stock.

In other news, EVP Brian J. Blaser sold 15,100 shares of Abbott Laboratories stock in a transaction dated Tuesday, July 24th. The shares were sold at an average price of $63.96, for a total value of $965,796.00. Following the completion of the transaction, the executive vice president now owns 151,718 shares of the company’s stock, valued at approximately $9,703,883.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Jaime Contreras sold 64,268 shares of Abbott Laboratories stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $66.84, for a total transaction of $4,295,673.12. Following the completion of the transaction, the senior vice president now directly owns 125,471 shares of the company’s stock, valued at approximately $8,386,481.64. The disclosure for this sale can be found here. In the last three months, insiders sold 90,389 shares of company stock valued at $5,995,012. Insiders own 0.74% of the company’s stock.

Several equities research analysts have issued reports on ABT shares. Zacks Investment Research lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, July 23rd. Sanford C. Bernstein started coverage on shares of Abbott Laboratories in a research note on Wednesday, June 27th. They issued an “outperform” rating and a $73.00 price target on the stock. Stifel Nicolaus lifted their price target on shares of Abbott Laboratories from $71.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 19th. Finally, Royal Bank of Canada reiterated a “buy” rating and issued a $70.00 price target on shares of Abbott Laboratories in a research note on Thursday, July 19th. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $69.88.

Shares of ABT opened at $66.21 on Friday. Abbott Laboratories has a one year low of $51.29 and a one year high of $67.36. The stock has a market capitalization of $116.15 billion, a PE ratio of 26.48, a PEG ratio of 1.85 and a beta of 1.48. The company has a quick ratio of 1.16, a current ratio of 1.58 and a debt-to-equity ratio of 0.64.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, July 18th. The healthcare product maker reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.02. Abbott Laboratories had a net margin of 3.13% and a return on equity of 15.30%. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.71 billion. During the same quarter last year, the firm posted $0.62 EPS. The company’s quarterly revenue was up 17.0% on a year-over-year basis. research analysts forecast that Abbott Laboratories will post 2.88 earnings per share for the current fiscal year.

Abbott Laboratories Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Featured Article: What does earnings per share mean?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.